NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.84 -0.52 (-0.62%) GOLD FUTURES
2,328.90 -13.20 (-0.56%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,433.52 -1,807.35 (-3.39%)
Infinity Pharmaceuticals, Inc. (I3F.F)
| Previous close | 0.0171 |
| Open | 0.0171 |
| Bid | 0.0000 x 520000 |
| Ask | 0.0000 x 520000 |
| Day's range | 0.0171 - 0.0171 |
| 52-week range | 0.0110 - 1.3150 |
| Volume | |
| Avg. volume | 4,109 |
| Market cap | 1.788M |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings date | 29 Apr 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.29 |
- Business Wire
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
CAMBRIDGE, Mass., July 25, 2023--Infinity Pharmaceuticals today announced a series of actions designed to reduce burn rate and enhance ability to maximize value of eganelisib
- Business Wire
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
CAMBRIDGE, Mass., July 24, 2023--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI").
- Business Wire
Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma
CAMBRIDGE, Mass., July 14, 2023--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI") at the special meeting of Infinity stockholders held earlier today (the "Special Meeti
